BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 35778697)

  • 21. Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer.
    Yue Q; Zhang Y; Bai J; Duan X; Wang H
    Dis Markers; 2022; 2022():7765900. PubMed ID: 35774851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
    Yu ZL; Zhu ZM
    Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
    Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
    Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
    Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
    Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
    [No Abstract]   [Full Text] [Related]  

  • 25. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
    Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
    Front Oncol; 2021; 11():710767. PubMed ID: 34458149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A N6-methyladenosine-related long noncoding RNAs model for predicting prognosis in oral squamous cell carcinoma: Association with immune cell infiltration and tumor metastasis.
    Yang Q; Cheng C; Zhu R; Guo F; Lai R; Liu X; Li M
    Oral Oncol; 2022 Apr; 127():105771. PubMed ID: 35189585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer.
    Wu J; Cai Y; Zhao G; Li M
    J Clin Lab Anal; 2021 Jun; 35(6):e23779. PubMed ID: 33934391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
    Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
    BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
    Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
    J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
    Huang X; Wang HF; Huang S
    Front Genet; 2022; 13():906880. PubMed ID: 36061188
    [No Abstract]   [Full Text] [Related]  

  • 31. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
    Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
    Front Immunol; 2021; 12():806189. PubMed ID: 35095893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of m6A-Related lncRNAs Associated With Prognoses and Immune Responses in Acute Myeloid Leukemia.
    Li D; Liang J; Cheng C; Guo W; Li S; Song W; Song Z; Bai Y; Zhang Y; Wu X; Zhang W
    Front Cell Dev Biol; 2021; 9():770451. PubMed ID: 34869365
    [No Abstract]   [Full Text] [Related]  

  • 33. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
    Wu ZY; Shi ZY
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new risk model based on a 11-m
    Lei L; Li N; Yuan P; Liu D
    BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
    Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
    BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs.
    Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T
    Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 38. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
    Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
    BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
    Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
    Front Immunol; 2021; 12():637933. PubMed ID: 33746977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.